Journal of Clinical Pharmacy and Therapeutics

Graphical Abstract A total of 105 recurrent spontaneous abortion (RSA) patients who received tumour necrosis factor inhibitor (TNFi) + intravenous immunoglobin (IVIG) + Heparin (enoxaparin) (n = 48) or IVIG+Heparin (enoxaparin) (n = 57) were retrospectively included in this two-centre cohort study. Live birth rate was increased in the TNFi+IVIG+Heparin group compared to the IVIG+Heparin group (72.9% vs. 52.6%). After adjustment by the multivariate logistic regression model, TNFi+IVIG+Heparin was also superior to IVIG+Heparin regarding the increased live birth rate. However, other obstetric outcomes and adverse event incidence were of no difference between TNFi+IVIG+Heparin and IVIG+Heparin group.…